Melanoma (stage III or IV) - ipilimumab: final appraisal determination
After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Determination (FAD) on Ipilimumab for previously treated advanced (unresectable or metastatic) malignant melanoma and submitted it to the Institute.
The FAD has been sent to the formal consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it. Subject to any appeal by consultees, the FAD may be used as the basis for the Institute's guidance on the use of the appraised technology in the NHS in England and Wales.
Please note that the appeal period for this appraisal will close at 5pm on 16 November 2012
Melanoma (stage III or IV) - ipilimumab: final appraisal determination guidance
Melanoma (stage III or IV) - ipilimumab: response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)
Melanoma (stage III or IV) - ipilimumab: updated analysis with revised patient access scheme from Bristol Myers-Squibb
Melanoma (stage III or IV) - ipilimumab: revised addendum by Liverpool reviews and implementation group (LRiG)
Melanoma (stage III or IV) - ipilimumab: Bristol Myers-Squibb (PAS Submission)
Melanoma (stage III or IV) - ipilimumab: addendum by Liverpool reviews and implementation group (LRiG)
Melanoma (stage III or IV) - ipilimumab: consultee and commentator comments on the ACD
Melanoma (stage III or IV) - ipilimumab: expert comments on the ACD
Melanoma (stage III or IV) - ipilimumab: comments on the ACD received from the public through the NICE website
This page was last updated: 01 November 2012